Bausch Health Companies Inc. Common Stock (BHC)

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Bausch Health Companies reported its fourth-quarter results after Wednesday's closing bell. Here's a look at the details from the report:

Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.

IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders.

S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day.

Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb.

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off.

Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns.

Bank of Canada cuts key policy rate by 25 basis points to 4.25% and suggests further cuts if inflation continues to ease.

Bausch Health reports Q2 2024 GAAP EPS of $0.03, missing the consensus of $0.28. Revenue hits $2.403 billion, up 11% YoY. Piper Sandler downgrades BHC to Underweight with a price target of $3, citing concerns over debt maturing in 2027/2028 and Xifaxan's loss of exclusivity.

Although Bausch Health has denied rumors that it’s on the cusp of bankruptcy, BHC stock is nevertheless suffering from skepticism.

Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market Committee (FOMC) meeting signaled a potential interest

Bausch Health Companies Inc. (NYSE: BHC) is experiencing a sharp decline in its stock price Wednesday. The drop was triggered by a report suggesting the company is negotiating a potential prepackaged Chapter 11 bankruptcy with co-op creditors.

After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a slowdown in the upward momentum is in the cards.

The Dow Jones Industrial Average is down triple digits, while the S&P 500 Index eyes its worst daily percentage drop since September 2023.

A large red number on the bottom line attracted the wrong kind of investor attention for the company.